Featured Articles inthrombosis journals
Thrombosis and Haemostasis
IF 2021: 6.830
Diana A. Gorog, Ying X. Gue, Tze-Fan Chao, Laurent Fauchier, Jose Luis Ferreiro et al.
While there is a clear clinical benefit of oral anticoagulation in patients with atrial fibrillation (AF) and venous thromboembolism (VTE) in reducing the risks of thromboembolism, major bleeding events (especially intracranial bleeds) may still occur and be devastating.
TH Open
Thrombosis and Haemostasis的开放获取姊妹期刊
Apixaban Prophylactic Anticoagulation in Patients with Nephrotic Syndrome
Tess Van Meerhaeghe, Alexandre Cez, Karine Dahan, Emmanuel Esteve, Ismail Elalamy, Jean Jacques Boffa, Eleonore Ponlot
Nephrotic syndrome (NS) is associated with an increased risk of thromboembolic events (TEs), due to hemostatic derangements. The use of direct oral anticoagulants (DOACs) in the prevention of TE has not been studied intensively in patients suffering from NS.
Seminars in Thrombosis and Hemostasis
IF 2021: 6.398
Hanny Al-Samkari
This review article and practical evidence-based guide aim to fill this unaddressed need, synthesizing published data on the use of antiangiogenic agents in HHT, relevant data for their use outside of HHT, and expert guidance where evidence is lacking.
Hämostaseologie
IF 2021: 2.145
Rebecca A. Mellema , Jacob Crandell , Aaron C. Petrey
This review summarizes the current knowledge of platelet alterations observed in the context of COVID-19 and their impact upon disease pathobiology.